Gilead Sciences is at the forefront of addressing significant public health challenges, particularly in the fields of virology, oncology, and inflammation. The company has made groundbreaking advancements in HIV treatment and prevention, including the development of the first once-daily oral medication for pre-exposure prophylaxis (PrEP), which has transformed HIV prevention strategies globally. Gilead's commitment to innovation is evident in its extensive research and development programs aimed at creating long-acting therapies and exploring potential pathways to cure HIV. The company actively collaborates with communities affected by HIV to ensure that its research addresses the needs of diverse populations, thereby enhancing access to effective treatments.

In addition to its focus on HIV, Gilead is also dedicated to advancing therapies for hepatitis C and various cancers. The company boasts a robust pipeline of over 50 clinical programs, reflecting its commitment to scientific innovation and health equity. Gilead's philanthropic efforts further underscore its mission, as it is one of the largest private funders of HIV-related programs worldwide. By investing in world-class science and fostering partnerships with community organizations, Gilead aims to eliminate barriers to care and improve health outcomes for individuals impacted by these diseases, ultimately striving to create a healthier world for all.

United States

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Cancer

Digestive System Diseases

Hematologic Diseases

Immune System Diseases

Infectious Diseases

Inflammatory disorders

Liver Diseases

Lung Diseases

Urogenital Diseases

Gilead Sciences

Liver disease

Non-alcoholic steatohepatitis

Primary biliary cholangitis

Primary sclerosing cholangitis

Seladelpar is uniquely suited as a potential treatment for inflammatory liver diseases. In the liver, PPARδ is expressed in multiple cell types including: hepatocytes, cholangiocytes, Kupffer cells and stellate cells. Preclinical and clinical data support its effect on regulating genes involved in bile acids synthesis, inflammation, fibrosis and lipid metabolism, storage and transport.

Livdelzi (Seladelpar)

Acute lymphoblastic leukemia

B-cell acute lymphoblastic leukemia

Leukemia

Tecartus is an autologous, anti-CD19 CAR T-cell therapy. Tecartus uses the XLP™ manufacturing process that includes T cell enrichment, a necessary step in certain B-cell malignancies in which circulating lymphoblasts are a common feature. Tecartus is also being evaluated in pediatric ALL, where its use is investigational, and its safety and efficacy have not been established.

Tecartus® (brexucabtagene autoleucel) (CAR-T)

COVID-19

Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized to form the pharmacologically active nucleoside triphosphate metabolite. Metabolism of remdesivir to remdesivir triphosphate has been demonstrated in multiple cell types. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. Remdesivir triphosphate is a weak inhibitor of mammalian DNA and RNA polymerases with low potential for mitochondrial toxicity (<a href="https://www.fda.gov/media/137566/download" rel="noopener" target="_blank">source - FDA</a> (section 14.1 / page 29)).

Veklury® (Remdesivir)

Human immunodeficiency virus

Lenacapavir is Gilead’s potential first-in-class, investigational long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection. Lenacapavir's multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for the development of long-acting therapy options for people living with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle.

Lenacapavir capsid inhibitor (GS-6207) 

B-cell lymphoma

Lymphopenia

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy. car t. car-t. cart.

Yescarta®

Breast cancer

ER+/HER2- breast cancer

Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.

Trodelvy® (sacituzumab govitecan-hziy) 

Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available, offering simple once-daily dosing with or without food, with a limited drug interaction potential and a high barrier to resistance. Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone. Biktarvy is a complete STR and should not be taken with other HIV medicines.

Biktarvy

Chronic hepatitis B

Vemlidy (Tenofovir Alafenamide)

Lenacapavir

Obeldesivir is an investigational novel oral antiviral being developed for the treatment of COVID-19, which once metabolized, works in the same way as Veklury by targeting SARS-CoV-2 virus replication through inhibition of the viral RNA polymerase.

Obeldesivir (GS-5245)

Multiple myeloma

Anito-cel

Urothelial cancer

Trodelvy® (sacituzumab govitecan-hziy; SG)

Triple-negative breast cancer

Trodelvy + Keytruda  

Metastatic breast cancer

Trodelvy® (Sacituzumab govitecan-hziy)

Hepatitis Delta Virus

Blocks the NTCP receptor on the surface of hepatocytes and prevents the entry of HBV/HDV into hepatocytes and viral spread within the liver. Hepcludex is administered subcutaneously as monotherapy or in patients being treated with a nucleoside/nucleotide analogue.

Bulevirtide (Hepcludex®)

Yescarta

Colorectal cancer

Etrumadenant

Non-small cell lung carcinoma

Trodelvy® (sacituzumab govitecan-hziy) comb w/KEYTRUDA® 

Sunlenca (Lenacapavir)

Sunlenca (Lenacapavir) + Islatravir

High risk myelodysplastic syndromes

Magrolimab is a potential, first-in-class investigational monoclonal antibody that binds to CD47. The primary mechanism of action of magrolimab is to block the inhibitory CD47-signal regulatory protein (SIRPα) interaction, enhancing the ability of macrophages and other phagocytes to identify and destroy foreign and malignant cells, with the goal of blocking the “don’t eat me” signal used by cancer cells. Magrolimab is a novel immunotherapy being developed in several hematologic cancers and solid tumor malignancies.

Gilead Sciences

Company Details